There was no evidence that COMT Val158Met polymorphism increases the risk of ovarian cancer (p=0.73), and Goodman et al. (15) implied that advance studies are required to explain different combinations of polymorphisms in estrogen metabolizing enzymes. The gene discussed is COMT; the disease is ovarian cancer.